Sibylla Biotech lures ex-Bayer CEO, Dieter Weinand, to be its chairman

Privately-held Italian firm Sibylla Biotech today announced the appointment of Dieter Weinand as chairman of its board of directors.

Mr Weinand’s background includes serving as president, chief executive and chairman of the board of Germany’s Bayer (BAYN: DE). At Sibylla, Mr Weinand’s profound knowledge will guide the board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of challenging therapeutic areas.  Mr Weinand has held significant senior management roles at Bristol-Meyers Squibb (NYSE: BMY), Pfizer (NYSE: PFE) and other leading big pharma companies.

“Having an industry leader of Dieter’s stature head our Board underscores the potential of Sibylla’s technology to reshape the drug discovery landscape by unlocking access to a range of previously undruggable targets. Dieter’s demonstrated success in driving value from R&D to the commercialization of impactful medicines will guide the next stages of Sibylla’s growth as we advance our pipeline of folding interference small molecules in preclinical studies. Personally, I will be honored to have him at our side,” said Lidia Pieri, co-founder and chief executive of Sibylla Biotech.